. 2013 Nov 26;13:560. doi: 10.1186/1471-2334-13-560

Table 2.

Alternative antifungal agents given after treatment failure with Voriconazole or LAmB

Reason for treatment failure	Alternative given
Reason for treatment failure	Voriconazole arm	LAmB arm
Infusion-related reactions^a	Caspofungin^b	Voriconazole^c
Nephrotoxicity	Caspofungin^b	Caspofungin^b
Hepatotoxicity	LAmB^d	Caspofungin^b
Suspected fungal infection	LAmB^e	Voriconazole^c
Persistent fever	LAmB^e	Voriconazole^c
Breakthrough fungal infection
Aspergillus spp.	LAmB^d	Voriconazole^c
Candida spp.	Caspofungin^b	Caspofungin^b
Zygomycetes spp.	LAmB^e	N/A
DematiaceousMoulds	N/A	LAmB plus posaconazole^f
Moulds not identified	N/A	LAmB^e
Non-responding baseline fungal infection
Aspergillus spp.	LAmB^d	Voriconazole^c
Candida spp.	Caspofungin^b	Caspofungin^b
Zygomycetes spp.	LAmB plus posaconazole^f	N/A
Trichoderma fungemia	N/A	Voriconazole^c
Fusarium spp.	N/A	LAmB plus posaconazole^f
Moulds not identified	N/A	LAmB plus posaconazole^f

^aA switch to alternative therapy due to infusion-related reactions included commencement of pre-dose diphenhydramine; ^bCaspofungin dose 70 mg on day one, 50 mg thereafter; ^cVoriconazole dose 6 mg/kg i.v. twice daily on day one, 4 mg/kg i.v. twice daily or 400 mg p.o. twice daily thereafter (22% in base case received oral voriconazole); ^dLAmB dose 3 mg/kg/day; ^eLAmB 5 mg/kg/day; ^fLAmB dose 5 mg/kg/day, posaconazole 200 mg four times per day.